Related Experiment Video
Updated: May 3, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 5, 2010
34.4K
Beta-blocking autoantibodies in pediatric bronchial asthma
The Journal of Allergy and Clinical Immunology
|September 1, 1984
Summary
Approximately 5% of children with asthma produce beta-blocking autoantibodies that interfere with beta-adrenergic receptors. This finding offers new insights into autoimmune responses in juvenile asthma.
Area of Science:
- Immunology
- Pulmonology
- Pharmacology
Background:
- Asthma is a chronic respiratory disease affecting millions of children worldwide.
- The role of autoantibodies in the pathogenesis of asthma is not fully understood.
- Beta-adrenergic receptors play a crucial role in bronchodilation and airway smooth muscle function.
Purpose of the Study:
- To investigate the prevalence of beta-blocking autoantibodies in children with asthma.
- To determine if these autoantibodies are associated with asthma severity.
- To explore the potential autoimmune component in juvenile asthma.
Main Methods:
- A binding inhibition assay was developed using iodohydroxybenzylpindolol and canine lung-plasma membrane beta-adrenergic receptors.
- Sera from 376 children with mild to severe asthma were tested for beta-blocking autoantibodies.
- Immunodepletion of IgG and IgA was performed on selected sera to confirm antibody activity.
Main Results:
- The study identified beta-blocking autoantibodies in approximately 5% of the studied juvenile asthmatic population.
- The binding inhibition assay demonstrated significant reduction in receptor binding in the presence of these autoantibodies.
- Immunodepletion confirmed the role of immunoglobulins (IgG and IgA) in the observed beta-blocking activity.
Conclusions:
- A subset of children with asthma produces autoantibodies that can block beta-adrenergic receptors.
- These findings suggest an autoimmune mechanism may contribute to asthma in some pediatric patients.
- Further research is warranted to explore the clinical implications and therapeutic targets related to these autoantibodies.
Related Concept Videos
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
1.7K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.7K
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.8K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.8K
01:28Antihypertensive Drugs: Types of β-Blockers
2.0K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K
01:20Asthma: Pathogenesis and Management
1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
2.1K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
2.1K
01:19Antiasthma Drugs: Leukotriene Modifiers
2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.2K